17. September 2021 by kmoeller 0 Comments

Welcome Mika

We are very pleased to welcome Mika, a successful healthcare company, to our portfolio. With this Berlin-based startup, we now have a total of 20 portfolio companies in both funds. Mika is the first and so far only digital health application (DiGA) for all types of cancer and can therefore be used as an oncological "app on prescription", prescribable and free of charge. It helps patients to go through cancer therapy in an informedmotivated and self-determined way. 

 

Who is Mika?

Mika accompanies patients during and after cancer therapyMonitoring symptoms , mindfulnessand movement exercises, answers to difficult questions - Mika helps to better cope with the mental and physical consequences of the disease. Mika is the first oncology appapproved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a digital health application for all types of cancer . Mika is being developed in close collaboration with leading oncologists, psychooncologists and cancer researchers at Charité, Leipzig University Hospital and NCT Heidelberg.

What makes Mika interesting?

The Mika app enables personalized therapy supportby combining symptom monitoring, reliable information and psycho-oncological coaching with innovative machine learning technologies.  

Mika is a approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a digital health application (DiGA) and is reimbursed as an "app on prescription" by statutory health insurers. With scientifically sound content, validated therapy management techniquesand secure data protection, sufferers are provided with a trustworthy digital cancer assistant that guides them through therapy in a targeted manner.     

The Mika app was also voted Most Innovative Product 2021 in the DiGA category at this year's Pharma Trend Images & Innovation Awards. At the same time, Mika won bronze at the MSD Health Award.

We are looking forward to supporting the strong team around the two founders Gandolf Finke and Jan Simon Raue in their further development.